나라바이오

비상장계속사업자

NARABIO Co.,Ltd.

김일호

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

나라바이오

Business Reg. No. 1978800980 · CEO 김일호

I.Investment Overview

Target나라바이오 (1978800980)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명나라바이오
영문명NARABIO Co.,Ltd.
대표자김일호
사업자등록번호1978800980
법인등록번호2101110131898
설립일2018.04.04

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW93202187.4202249.7202347.62024302025
영업이익100M KRW5.3202142022-21.82023-19.72024-8.32025
순이익100M KRW4.320211.92022-28.72023-63.82024-5.22025
Item20252024202320222021
자산총계171.1억원182.3억원252.4억원254억원239.7억원
부채총계202.2억원196.6억원202.9억원194억원182.7억원
자본총계-31.1억원-14.3억원49.5억원60억원57억원
매출액30억원47.6억원49.7억원87.4억원93억원
영업이익-8.3억원-19.7억원-21.8억원4억원5.3억원
순이익-5.2억원-63.8억원-28.7억원1.9억원4.3억원

VI.Financial Ratios

FY2025 basis

-27.53%

영업이익률

-17.17%

순이익률

-3.01%

ROA

ROE

부채비율

자기자본비율

VII.R&D Activity

Fields 농림수산식품 > 농생물학

Keywords 표고버섯, 골대사, 맞춤형제품

YearProjectsPapersPatents
2019100

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

나라바이오 투심보고서 | Alpha Lenz